3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-(((benzyloxy)carbonyl)amino)propanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-(((benzyloxy)carbonyl)amino)propanoic acid
• 英文别名: 3-(9H-fluoren-9-ylmethoxycarbonylamino)-2-(phenylmethoxycarbonylamino)propanoic acid
• 化学式: C₂₆H₂₄N₂O₆
• 分子量: 460.486
• InChiKey: MVKNXKRRMCSKJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  哌嗪 、 5-[[芴甲氧羰基]氨基]戊酸 、 对硝基苯基氯甲酸酯 、 3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-(((benzyloxy)carbonyl)amino)propanoic acid 生成
  参考文献：
  名称：

  Solid-phase synthesis of a selective αvβ3 integrin antagonist library

  摘要：

  Solid-phase synthesis was used to generate a focused RGD peptide mimetic library in an effort to identify potent and selective alpha(v) beta(3) integrin antagonists. Increased activity was observed for compounds possessing a urea linkage to piperazine, with the most active compound (28) exhibiting an IC50 = 1.1 nM in an alpha(v) beta(3) ELISA assay. (C) 1997 The DuPont Merck Pharmaceutical Company. Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00200-x

文献信息

• HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS
  申请人：Lennig Petra

  公开号：US20070197539A1

  公开（公告）日：2007-08-23

  The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments

  该发明涉及用氨基酸取代的六氢吡嗪[1,2-a]嘧啶-4,7-二酮衍生物，以及其生理耐受盐，其制备方法以及作为药物的用途。
• [EN] BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES DE BENZIMIDAZOLE UTILISES COMME ANTAGONISTES DU RECEPTEUR DE LA VITRONECTINE
  申请人：SCHERING CORP

  公开号：WO2000032578A1

  公开（公告）日：2000-06-08

  The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R?1, R2, R3 and R4¿ are H or specified substituents; R?5, R6, R7, R8, R9, R10, R11 and R12¿ are independently selected from H or C¿1?-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.

  本发明提供具有式(I)的化合物，其中n，p，q和r各自独立地选自0或1；a，b，c和d各自独立地表示碳或氮原子，但a，b，c和d中不超过两个是氮原子；Y和Y'各自独立地表示从烷基，烷氧基，卤素，-CF3和-C（O）OH中选择的1-4个可选取代基；R?1，R2，R3和R4¿为H或指定的取代基；R?5，R6，R7，R8，R9，R10，R11和R12¿各自独立地选自H或C¿1?-C3烷基；或其生物可降解酯或其药学上可接受的盐。还提供使用这些化合物治疗玻璃蛋白酶介导的疾病的方法，例如癌症，视网膜病变，动脉粥样硬化，血管再狭窄和骨质疏松症。
• BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS
  申请人：SCHERING CORPORATION

  公开号：EP1135374B9

  公开（公告）日：2007-02-21
• US6204282B1
  申请人：——

  公开号：US6204282B1

  公开（公告）日：2001-03-20
• US7994168B2
  申请人：——

  公开号：US7994168B2

  公开（公告）日：2011-08-09